# Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

Source: https://onco.cc/trials/nct03190941/  
OnCo record `nct03190941` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of cyclophosphamide, fludarabine and aldesleukin (high-dose IL-2) in pancreatic cancer, run by National Cancer Institute (NCI), now recruiting.

## Summary

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients is a phase 1/2, interventional study registered as NCT03190941 by National Cancer Institute (NCI), with a registry enrolment figure of 110 participants, started 2017-09-21 and due to reach its primary completion in 2027-06-29. Interventions recorded: Cyclophosphamide; Fludarabine; Anti-KRAS G12V mTCR PBL; Aldesleukin. Conditions listed: Pancreatic Cancer; Gastric Cancer; Gastrointestinal Cancer; Colon Cancer; Rectal Cancer. Primary outcome: Response rate; Frequency and severity of treatment-related adverse events. Pancreatic eligibility wording from the registry: "* Patients with pancreatic cancer must have received gemcitabine, 5FU, and oxaliplatin (or similar agents), or have contraindications to receiving those medications". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT03190941
- Phase: 1/2
- Setting: A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
- Sponsor: National Cancer Institute (NCI)
- Enrolled: 110

## Sources

- ClinicalTrials.gov NCT03190941: https://clinicaltrials.gov/study/NCT03190941

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Aldesleukin (high-dose IL-2)](https://onco.cc/drugs/aldesleukin/), [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Fludarabine](https://onco.cc/drugs/fludarabine/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct03190941.json